Ticker > Company >

Sarthi Pharma share price

Sarthi Pharmaceuticals Ltd.

SECTOR: Pharmaceuticals & Drugs  1.66 K   0   0

0
0 0

Price Summary

Today's High

₹ 0

Today's Low

₹ 0

52 Week High

₹ 0

52 Week Low

₹ 0

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

0 Cr.

Enterprise Value

-0.01 Cr.

No. of Shares

0 Cr.

P/E

0

P/B

0

Face Value

₹ 0

Div. Yield

0 %

Book Value (TTM)

₹  -106.26

CASH

0.01 Cr.

DEBT

0 Cr.

Promoter Holding

-

EPS (TTM)

₹  4.86

Sales Growth

2379.77%

ROE

0.35 %

ROCE

0.35%

Profit Growth

-36.26 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 YearNA
3 YearNA
5 YearNA

Profit Growth

1 YearNA
3 YearNA
5 YearNA

ROE%

1 Year0.35%

ROCE %

1 Year0.35%

Debt/Equity

0

Price to Cash Flow

NaN

Interest Cover Ratio

77.546224417784

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Investors List
 Share Holding Data is not available for this company.Report us
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 21.8541415389901 days.
  • Company has a healthy liquidity position with current ratio of 7.81618828733864.

 Limitations

  • The company has shown a poor profit growth of 0% for the Past 3 years.
  • The company has shown a poor revenue growth of 0% for the Past 3 years.
  • Company has a poor ROE of 0% over the past 3 years.
  • Company has a poor ROCE of 0% over the past 3 years
  • The company has a low EBITDA margin of 0% over the past 5 years.

Quarterly Result (All Figures in Cr.)

 Quarterly Data is not available for this company.Report us

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2014
Net Sales 0.26
Total Expenditure 0.25
Operating Profit 0.01
Other Income 0
Interest 0
Depreciation 0
Exceptional Items 0
Profit Before Tax 0.01
Tax 0
Net Profit 0.01
Adjusted EPS (Rs.) 0.03

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2014
Equity and Liabilities
Share Capital 3.55
Total Reserves -0.44
Borrowings 0
Other N/C liabilities 0
Current liabilities 0.01
Total Liabilities 3.11
Assets
Net Block 0
Capital WIP 0
Intangible WIP 0
Investments 2.83
Loans & Advances 0.24
Other N/C Assets 0
Current Assets 0.05
Total Assets 3.11
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2014
Profit from operations 0
Adjustment 0
Changes in Assets & Liabilities 0
Tax Paid 0
Operating Cash Flow 0
Investing Cash Flow 0
Financing Cash Flow 0
Net Cash Flow 0

Corporate Actions

Investors Details

 No Promoters Data available for this company.Report us
 No Investors Data available for this company.Report us

Annual Reports

Title Link
Title Link
 No Annual reports exist for this company.Report us

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit and Research reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation and Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

 No Latest News available for this company.Report us

Sarthi Pharma Stock Price Analysis and Quick Research Report. Is Sarthi Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Sarthi Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Sarthi Pharma has a PE ratio of 0 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Sarthi Pharma has ROA of 0.344894530863897% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Sarthi Pharma has a Current ratio of 7.81618828733864.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Sarthi Pharma has a ROE of 0.349680581911611%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Sarthi Pharma has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Sarthi Pharma has reported revenue growth of 2379.77348613878% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Sarthi Pharma for the current financial year is 4.15784684455705%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Sarthi Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Sarthi Pharma is Rs 0. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Sarthi Pharma in Ticker for free. Also, one can get the intrinsic value of Sarthi Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Sarthi Pharma FAQs

Q1. What is Sarthi Pharma share price today?
Ans: The current share price of Sarthi Pharma is Rs 0.

Q2. What is the market capitalisation of Sarthi Pharma?
Ans: Sarthi Pharma has a market capitalisation of Rs 0 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Sarthi Pharma?
Ans: The PE ratio of Sarthi Pharma is 0 and the P/B ratio of Sarthi Pharma is 0, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Sarthi Pharma share?
Ans: The 52-week high share price of Sarthi Pharma is Rs 0, and the 52-week low share price of Sarthi Pharma is Rs 0.

Q5. Does Sarthi Pharma pay dividends?
Ans: Currently, Sarthi Pharma does not pay dividends. Dividend yield of Sarthi Pharma is around 0%.

Q6. What are the face value and book value of Sarthi Pharma shares?
Ans: The face value of Sarthi Pharma shares is Rs 10, while the book value per share of Sarthi Pharma is around Rs 0. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Sarthi Pharma?
Ans: Sarthi Pharma has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Sarthi Pharma?
Ans: The ROE of Sarthi Pharma is 0.349680581911611% and ROCE of Sarthi Pharma is 0.349978249579404%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Sarthi Pharma a good buy for the long term?
Ans: The Sarthi Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Sarthi Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Sarthi Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Sarthi Pharma’s financials?
Ans: You can review Sarthi Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Sarthi Pharma
X